| Species |
Human |
| Protein Construction |
IL-6 R alpha/CD126 (Leu20-Pro365)
Accession # P08887-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human IL6 at 2μg/ml (100μl/Well) on the plate can bind IL-6 R alpha/CD126 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
65.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 85-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Serum levels of interleukin-6 (IL-6) are increased in patients with type 2 diabetes (T2D). IL-6 exerts its pleiotropic effects via the IL-6 α-receptor (IL-6R), which exists in membrane-bound and soluble (sIL-6R) forms and activates cells via the β-receptor glycoprotein 130 (gp130). |
| Synonyms |
IL-6R subunit alpha; IL-6R-alpha; IL-6RA; IL-6R 1; IL6R; CD126; IL6RQ; gp80 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
